Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humabs isolates antibody targeting all influenza A viruses

This article was originally published in Scrip

Executive Summary

Humabs BioMed, a Swiss biotech that includes Chiron founder and seasoned veteran Bill Rutter as a backer, has secured exclusive worldwide rights to a technology that could yield a universal flu treatment. The approach is based on a neutralising antibody selected from plasma cells that binds to all 16 subtypes of group 1 and group 2 influenza A haemagglutinins. Details of the isolated antibody, dubbed F16 and achieved by researchers working in British and Swiss laboratories, have been published on-line in Science.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC013898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel